MPR Weekly Dose #69 - False and misleading pharma promo; Novel LDL-C therapy; Heart failure Tx expanded; Migraine device okay’d for teens.

<p><span style="font-weight: 400;">An FDA warning over pharma company's promo material; Entresto's approval is expanded, There’s approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device for OK'd for teens.</span></p>